Successful Use of Maribavir for Secondary CMV Prophylaxis in a Pediatric HSCT Patient (ASPHO 2025) - May 13, 2025 - "Despite Letermovir prophylaxis, she developed CMV viremia post-HSCT, leading to primary engraftment failure. She received Foscarnet and Ganciclovir before transitioning to maribavir as secondary prophylaxis during her second HSCT... This case represents the first reported use of maribavir as secondary CMV prophylaxis in a pediatric HSCT patient, demonstrating its safety and efficacy in managing CMV viremia without compromising engraftment or exacerbating comorbidities. Further research is warranted to explore maribavir's role in earlier-stage CMV management and pediatric populations."
Clinical • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Otorhinolaryngology • Pediatrics • Respiratory Diseases • Sinusitis • Transplant Rejection
|
|
Lind KT; Broadman J; Barthelmess Goodell E; Strommen A; Curtis D; McLaughlin L
|